Xigduo XR Shortage Update: What Patients Need to Know in 2026

Patients and caregivers searching for Xigduo XR at pharmacies in 2026 are encountering a confusing situation: no official FDA shortage, but inconsistent availability that varies widely depending on where you live, which pharmacy you use, and whether you're looking for the brand or new generic version.

This update covers everything you need to know: what's actually happening with Xigduo XR availability, why it matters, and your most effective options right now.

Current Status: Is Xigduo XR in Official Shortage?

As of 2026, the FDA has not placed Xigduo XR on its official drug shortage list. This is an important distinction. An official FDA shortage means a commercially important medical product is in actual shortage, typically due to manufacturing failures, recalls, or supply chain disruptions severe enough to affect patient care nationally.

However, individual pharmacy stockouts — where a specific pharmacy doesn't have the medication in stock — can still happen even without an official shortage declaration. Many patients experience this as a "shortage" even when the medication is technically available somewhere nearby.

Why Are Patients Having Trouble Finding Xigduo XR?

Several converging factors are making Xigduo XR harder to fill for many patients in 2026:

The Brand-to-Generic Transition

In early 2026, the FDA approved generic dapagliflozin/metformin hydrochloride extended-release tablets. This is good news overall — generics will lower costs and expand supply over time. But during the transition, some pharmacies have reduced their brand inventory in anticipation of stocking generics, while generics are still being distributed. This creates a temporary gap where neither brand nor generic is consistently available at every pharmacy.

Insurance Coverage Complications

Most Medicare Part D plans and many commercial insurance plans do not routinely cover brand-name Xigduo XR. Some require prior authorization; others use step therapy requiring trials of preferred alternatives first. When a patient's insurance changes at the start of a new benefit year (January 1), prescription access can be disrupted unexpectedly.

Additionally, some formularies changed in 2026 to either add the generic dapagliflozin/metformin ER or reclassify the brand Xigduo XR to a higher cost tier. These changes can temporarily disrupt patient access as prescriptions are updated.

Increasing Overall Demand for Dapagliflozin Products

Dapagliflozin — the SGLT2 inhibitor in Xigduo XR — has dramatically expanded its clinical indications since its 2014 approval for type 2 diabetes. It is now also FDA-approved for heart failure (2020) and chronic kidney disease (2021). This means endocrinologists, cardiologists, and nephrologists are all prescribing it simultaneously, driving demand across all dapagliflozin-containing products.

The combination tablet — Xigduo XR — represents just one part of the dapagliflozin market. When supply is tight, pharmacies prioritize the higher-volume standalone Farxiga tablets over the combination product, affecting Xigduo XR availability disproportionately.

Pharmacy-Level Inventory Decisions

Not every pharmacy stocks every medication. Pharmacies make inventory decisions based on local prescription volume. If fewer patients at a given pharmacy use Xigduo XR (perhaps because many have been switched to alternatives by insurance), the pharmacy may stop routinely stocking it. This means availability is highly localized — your nearest pharmacy might be out while one 10 miles away keeps it in stock.

What This Means If You're Running Low

If you're getting close to running out of Xigduo XR, act early. Here are the most effective steps:

Use medfinder: Visit medfinder.com and enter your medication and dosage. medfinder calls pharmacies near you to check stock and texts you the results.

Ask about the generic: Generic dapagliflozin/metformin ER is now available and bioequivalent. Ask your pharmacist specifically if they have it.

Contact your prescriber: Let them know you can't find it. They may prescribe the components separately or contact your insurer to expedite a prior authorization.

Try independent pharmacies: They often have different supply chains and can source medications that chain pharmacies can't access immediately.

Consider mail order: 90-day mail-order prescriptions often have more consistent supply and may be cheaper for covered medications.

Is the Availability Situation Improving?

Yes, the outlook is improving. Multiple generic manufacturers received FDA approval in early 2026. As generics ramp up production and distribution, more pharmacies will carry the medication at lower prices. Insurance formularies are gradually adding the generic to covered tiers, which will make it more accessible for insured patients.

The dapagliflozin/metformin ER market is worth roughly $514 million annually — there is strong economic incentive for manufacturers to keep supply robust once production is fully ramped up.

Bottom Line for Patients

There is no active FDA-declared shortage of Xigduo XR in 2026, but pharmacy-level availability is genuinely inconsistent. The situation is driven by the brand-to-generic transition, insurance coverage patterns, and high overall demand for dapagliflozin products. The availability outlook is improving, but in the meantime, being proactive about refills and knowing your alternatives makes all the difference.

For a deeper look at the underlying causes, read our article: Why is Xigduo XR so hard to find?